14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Tuesday, 7th May 2024 CANF stock ended at $2.07. This is 1.90% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 3.86% from a day low at $2.07 to a day high of $2.15.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Dec 13, 2022 $0.750 $0.780 $0.718 $0.734 56 811
Dec 12, 2022 $0.760 $0.760 $0.730 $0.740 48 098
Dec 09, 2022 $0.80 $0.80 $0.760 $0.775 24 179
Dec 08, 2022 $0.760 $0.780 $0.730 $0.742 69 642
Dec 07, 2022 $0.790 $0.80 $0.740 $0.760 115 165
Dec 06, 2022 $0.83 $0.84 $0.761 $0.761 29 563
Dec 05, 2022 $0.82 $0.84 $0.81 $0.82 16 972
Dec 02, 2022 $0.82 $0.84 $0.82 $0.83 7 225
Dec 01, 2022 $0.83 $0.84 $0.82 $0.83 13 516
Nov 30, 2022 $0.84 $0.86 $0.83 $0.84 2 418
Nov 29, 2022 $0.84 $0.87 $0.83 $0.83 35 906
Nov 28, 2022 $0.84 $0.87 $0.83 $0.84 40 154
Nov 25, 2022 $0.90 $0.90 $0.85 $0.87 18 620
Nov 23, 2022 $0.84 $0.86 $0.83 $0.85 26 175
Nov 22, 2022 $0.84 $0.85 $0.80 $0.81 30 511
Nov 21, 2022 $0.84 $0.84 $0.81 $0.83 22 266
Nov 18, 2022 $0.90 $0.90 $0.80 $0.83 13 960
Nov 17, 2022 $0.82 $0.82 $0.790 $0.81 27 166
Nov 16, 2022 $0.81 $0.83 $0.80 $0.82 14 292
Nov 15, 2022 $0.82 $0.82 $0.789 $0.82 45 684
Nov 14, 2022 $0.82 $0.83 $0.782 $0.80 33 523
Nov 11, 2022 $0.790 $0.83 $0.780 $0.797 23 792
Nov 10, 2022 $0.80 $0.80 $0.761 $0.790 58 619
Nov 09, 2022 $0.82 $0.83 $0.780 $0.790 62 917
Nov 08, 2022 $0.87 $0.87 $0.80 $0.82 33 702
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT